Targeting KRAS mutant tumors through inhibition of individual downstream pathways has
had limited clinical success. Here we report that RAF inhibitors exhibit little efficacy in KRAS …

Colorectal cancer (CRC) is a heterogeneous disease with a myriad of alterations at the
cellular and molecular levels. Kristen rat sarcoma (KRAS) mutations occur in up to 40% of …

Simple Summary A better understanding of the role of KRAS and its different mutations has
led to the development of specific small-molecule inhibitors able to target KRAS G12C, an …

The RAS gene family, responsible for signal transduction within the mitogen activated
protein kinase (MAPK) and phosphatidylinositol 3 kinase (PI3K) pathways, is frequently …

RAS family variants—most of which involve KRAS—are the most commonly occurring
hotspot mutations in human cancers and are associated with a poor prognosis. For almost …

Despite being the most frequently altered oncogenic protein in solid tumours, KRAS has
historically been considered 'undruggable'owing to a lack of pharmacologically targetable …

KRAS is one of the most frequently mutated oncogenes in cancer, being a potent initiator of
tumorigenesis, a strong inductor of malignancy, and a predictive biomarker of response to …

Investigating therapeutic" outliers" that show exceptional responses to anti-cancer treatment
can uncover biomarkers of drug sensitivity. We performed preclinical trials investigating …

KRAS is the most frequently mutated oncogene in human cancer, yet no therapies are
available to treat KRAS mutant cancers. We used two independent reverse genetic …

KRAS mutant tumors are largely recalcitrant to targeted therapies. Genetically engineered
mouse models (GEMMs) of Kras mutant cancer recapitulate critical aspects of this disease …